Rotigotine Discount Agreement (Open-House)
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Rotigotin (ATC-Code nach WHO: N04BC09)
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Supply of pharmaceutical products with active substance Rotigotine (ATC N04BC09)
- Conclusion of a non-exclusive discount agreement under §130a Abs. 8 SGB V
Afficher le résumé complet
This is a non-exclusive discount agreement (Rabattvereinbarung) for the active substance Rotigotine (ATC N04BC09), conducted as an Open-House model by AOK PLUS. The agreement is open to all interested pharmaceutical companies meeting the requirements, with no exclusivity and no guaranteed minimum purchase quantities. The procedure is not a formal public procurement but published for transparency. Participation is possible from the first deadline (03.12.2024) until the agreement ends (31.12.2026). The estimated contract value is not specified.
Risques
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
- Must have a registered seat in Germany, EU/EEA
Eligibility
- Must submit declaration of no exclusion grounds (§§123,124 GWB) and Russia sanctions compliance
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Rotigotine Discount Agreement (Open-House)
Non-exclusive discount agreement for Rotigotine (N04BC09) under §130a Abs. 8 SGB V, open to all qualified pharmaceutical companies. No minimum volume, no exclusive supply. Agreement ends 31.12.2026.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Siehe Kurzbeschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Rotigotin (ATC-Code nach WHO: N04BC09)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 10 Nov 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 684657-2024
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications